Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today...
-
-- First Clinical Trial to Test the Safety and Activity of Activated Allogeneic Donor Gamma-Delta (γδ) T cells for Cancer Immunotherapy -- NEW YORK, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Incysus,...
-
NEW YORK, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today...
-
HAMILTON, Bermuda, Aug. 24, 2017 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative γδ T cell immunotherapy for the treatment of cancers, today...
-
HAMILTON, Bermuda, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Incysus, Ltd, a biopharmaceutical company focused on delivering an innovative γδ T cell immunotherapy for the treatment of cancers, announced...
-
HAMILTON, Bermuda, April 12, 2017 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative off-the-shelf cellular therapy for the treatment of solid tumor...
-
HAMILTON, Bermuda, March 24, 2017 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative off-the-shelf cellular therapy for the treatment of solid tumor...